TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Image quality, as measured by tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Image quality, as measured by tumor-to-live contrast to noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recurrence of NS
Endpoint domain: Mortality/survival
Primary endpoint: Change in MYMOP2 score of the most troubling symptom of CIPN
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Pathological Response (pCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic Response Rate (Complete or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Lesion Contrast Enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Border Delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Internal Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scores on acuity tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: scores on spatial attention tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in NPI Psychosis Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Indicators of renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with sudden cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants receiving appropriate therapy from ICD for VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: delay between inclusion and intubation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Reduction in SNOT-20 Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of child wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of hypoglycaemia due to gliflozin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy measured by blood test-hemogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellularity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Isolation and characterization of B and T lymphocytes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of photoprotective function of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: non-relapse mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: cumulative microbial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight trajectory adjusted for time varying length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft volumetric stability change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Herniation thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse effect of interferon
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-tz (area under the concentration-time curve of BI 706321 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of BI 706321 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intervention-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Drop-out From Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Tolerated Dose (MTD) of Akt inhibitor MK-2206
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose (RPTD) of Akt inhibitor MK-2206
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of prolonged administration of Akt inhibitor MK-2206
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline in gastric half-emptying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Regular Menstrual Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Average Number of Bleeding Days Per Cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Participants' Overall Satisfaction With Vaginal Ring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of early rebleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social cognition scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of patients with RNFL decrease of 5 microns or more at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with RNFL decrease of 5 microns or more at month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Sustained Donor Engraftments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of pain palliation responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: free overall survival
Endpoint domain: Mortality/survival
Primary endpoint: free recurrence survival
Endpoint domain: Mortality/survival
Primary endpoint: Late onset sepsis (LOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Eyes With No Change in Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytotoxic and inhibitory activity against leukemic myeloblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of surgical implant
Endpoint domain: Adverse events/effects
Primary endpoint: Change scores of Box and Block test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores of Upper-extremity Fugl-Myer Assessment (UEFMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of RCN
Endpoint domain: Adverse events/effects
Primary endpoint: Mini Mental State Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inactivity of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of sexual and asexual stages of Plasmodium falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical outcomes (survival/toxicity)
Endpoint domain: Mortality/survival
Primary endpoint: Change in concentration of TNF-alpha (mRNA level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mineralization surface (MS%BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal rate of whole-body fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: no local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no palpable mass on clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic uptake and washout of 123-I AV83
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative Anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain induced by resisted wrist dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute and percentual number of regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Diabetes Behavior Rating Scale at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline HbA1c at 6 months and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Field Goal Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dribbles Performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Sprint Decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature oocytes collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinical symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiac MRI signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 minute walk distance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients achieving a complete molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-to-stand Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Minute Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Pain Score at 60 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Tolerability - Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerability - Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerability - Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerability - Roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: time to headache relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity using ETDRS charts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central retinal thickness (Optical coherence tomography)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF genotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with CDAI score of 220-450 at enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CDAI score during the observational period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Pelvic-ureter-units (PUUs) Detected With Vesicoureteral Reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Adverse Events Following Contrast Enhanced Voiding Urosonography
Endpoint domain: Adverse events/effects
Primary endpoint: Upper Extremity Functional Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: p-Src Tyr419 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successfully delivered accelerated partial breast irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of R0 resections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biopsy outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Fusion Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Best Ear Hearing Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Eligible for Neratinib Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IgE-blocking factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Foot eversion relative to shank during stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot external rotation relative to shank during stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endoscopist Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased Percent of Ventricular Pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biochemical variables GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Excess Weight Loss (EWL) by Body Mass Index (BMI) Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Responder Rate in the Treatment Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of overall tolerability rate on a 4-point scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in intensity of hyper pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in extension of hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metal ion concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-derived parasite multiplication rate (PMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Glucose (BG) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypoglycemia Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-21 day) of Patritumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Patritumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Electrophysiological Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Auditory-Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Mean Daily Number of Urination Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion using CPAP within 48-hours of stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glucagon responses to a meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucagon responses to insulin induced hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Beck depression inventory scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fat mass evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle mass evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary lifestyle questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of good adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Renal function damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urodynamic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients requiring Renal Replacement Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of subjects with confirmed bacterial or viral infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who consent to donate organs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ulcer surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior gingival exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of Aggression Against People and/or Property
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative flare up (pain and swelling)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Memory Cognitive Domain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: oral antihypertensive agents' dosage and type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Treatment Pathological Staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Video Behavior Coding of time on task
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Interface pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emitted dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reducing exogenous insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fast blood glucose (FBG) and postmeal blood glucose (PBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak movement speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatiotemporal movement variability (STI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Silicon Phthalocyanine 4
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiovascular complications in diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of oral prednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in the VAS Score From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Meal Calories Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of Sertraline and Telenzepine Combination
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pharmacokinetics (PKs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelium Dependent Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise of Self-Care Agency Scale (ESCA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coping and Adaptation Processing Scale (CAPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Number of Rejected Samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of PF-04991532
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose excursion in response to a liquid meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes